1. Home
  2. PRZO vs SCYX Comparison

PRZO vs SCYX Comparison

Compare PRZO & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ParaZero Technologies Ltd.

PRZO

ParaZero Technologies Ltd.

HOLD

Current Price

$1.26

Market Cap

25.1M

Sector

N/A

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.82

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRZO
SCYX
Founded
2014
1999
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.1M
26.3M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
PRZO
SCYX
Price
$1.26
$0.82
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
2.7M
557.3K
Earning Date
08-28-2025
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,007,440.00
$2,932,000.00
Revenue This Year
N/A
$170.77
Revenue Next Year
N/A
$286.38
P/E Ratio
N/A
N/A
Revenue Growth
80.42
N/A
52 Week Low
$0.53
$0.57
52 Week High
$2.15
$1.31

Technical Indicators

Market Signals
Indicator
PRZO
SCYX
Relative Strength Index (RSI) 49.82 78.74
Support Level $1.15 $0.63
Resistance Level $1.35 $0.68
Average True Range (ATR) 0.15 0.04
MACD 0.01 0.02
Stochastic Oscillator 39.73 89.62

Price Performance

Historical Comparison
PRZO
SCYX

About PRZO ParaZero Technologies Ltd.

ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: